Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Depreciation (2023 - 2024)

Historic Accumulated Depreciation for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to $1.7 million.

  • Contineum Therapeutics' Accumulated Depreciation rose 1624.92% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year increase of 1624.92%. This contributed to the annual value of $1.7 million for FY2024, which is 1624.92% up from last year.
  • Contineum Therapeutics' Accumulated Depreciation amounted to $1.7 million in Q4 2024, which was up 1624.92% from $1.5 million recorded in Q4 2023.
  • Contineum Therapeutics' 5-year Accumulated Depreciation high stood at $1.7 million for Q4 2024, and its period low was $1.5 million during Q4 2023.